PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma
This study intends to evaluate the application value of Positron Emission Tomography/Magnetic Resonance (PET/MR) in the staging and efficacy evaluation of NK/T cell lymphoma, aiming to explore a more accurate system for predicting the prognosis of patients and guiding the treatment.
| Condition(s) | NK/T-cell Lymphoma |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This study intends to evaluate the application value of Positron Emission Tomography/Magnetic Resonance (PET/MR) in the staging and efficacy evaluation of NK/T cell lymphoma, aiming to explore a more accurate system for predicting the prognosis of patients and guiding the treatment. |
| Who can participate | Inclusion Criteria: * Pathologically diagnosed NK/T-cell lymphoma based on the WHO classification 2016 * Age from 14 to 70 years-old * ECOG 0-2 score * Patients with a life expectancy of at least 6 months * Patient has not been treated before for NK/T cell lymphoma * Commit to abide by the research procedures and cooperate with the implementation of the whole process of research * Written informed consent Exclusion Criteria: \- Subjects who meet any of the following criteria are not eligible for study entry * Diagnosed aggressive NK cell leukemia * Pregnant or lactating women * Liver and kidney insufficiency * Other PET/MR contraindications: 1. Those with implanted functional electronic devices such as cardiac pacemakers 2. Carotid aneurysm clipping and other implants are ferromagnetic mat |
| Ages | 14 Years to 70 Years |
| Sex | All |
| Lead sponsor | Ruijin Hospital |
| Locations | Shanghai, Shanghai Municipality, China |
| Start date | 2023-05-26 |
| NCT ID | NCT05662540 |
| Official listing | https://clinicaltrials.gov/study/NCT05662540 |